Inhibrx Biosciences, Inc
INBX · United States
Share price · INBX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when INBX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 3 Nov 2026+12.4%
Nothing announced by INBX that day or the session before.
- 28 Oct 2026-23.4%
Nothing announced by INBX that day or the session before.
- 25 Aug 2026+16.9%
Nothing announced by INBX that day or the session before.
- 14 Aug 2026-8.9%
- 12 Aug 2026+6.5%
- 12 May 2026-14.8%
- 22 Apr 2026+36.9%
- 9 Apr 2026+12.8%
Nothing announced by INBX that day or the session before.
- 27 Mar 2026-11.2%
Nothing announced by INBX that day or the session before.
- 19 Mar 2026-5.6%
Share of unusual movement by asset
For each asset, the share of INBX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2/3 | OX40 (agonist)Monoclonal antibody | Non-Small Cell Lung CancerHead and Neck Squamous Cell Carcinoma | |
| Phase 2 | DR5 (TRAIL-R2)Other | Bone Cancer Conventional Chondrosarcoma |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
February 2027 (1)
What to watch
2029 (1)
December 2029 (1)
What to watch
2033 (1)
July 2033 (1)
What to watch
Regulatory and conference events
(5)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (11)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $2.0M | $26M | $199M | $39M-$35M operating cash flow | report ↗ |
View 10 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0 | $24M | $133M | $37M-$30M operating cash flow | report ↗ |
| 2026-Q1 | — | $25M | $162M | $33M-$38M operating cash flow | report ↗ |
| 2025-Q3 | $0 | $29M | $153M | $35M-$34M operating cash flow | report ↗ |
| 2025-Q2 | $1.3M | $22M | $187M | $29M-$30M operating cash flow | report ↗ |
| 2025-Q1 | $0 | $37M | $217M | $43M-$36M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $39M | $196M | $44M-$30M operating cash flow | report ↗ |
| 2024-Q2 | $0.1M | $68M | $227M | —-$57M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $64M | $252M | $79M-$63M operating cash flow | report ↗ |
| 2023-Q3 | $0.1M | $38M | $337M | $52M-$54M operating cash flow | report ↗ |
| 2023-Q2 | <$0.1M | $34M | $192M | $47M | report ↗ |
Annual history (4 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $1.3M | $113M | $124M | $35M-$130M operating cash flow | report ↗ |
Inhibrx Biosciences reported revenue of $1.3M for fiscal 2025, up 550.0% YoY from $0.2M, with R&D spend of $113.03M, down 44.5% YoY from $203.74M. Cash and equivalents were $124.22M at year-end, and the company reported a net loss of $140.05M with a quarterly net burn of $140.06M.
During the year, the company advanced ozekibart, with the ChonDRAgon trial meeting its primary endpoint in chondrosarcoma and a biologics license application planned for early the second quarter of 2026. It also plans FDA discussions in the second half of 2026 regarding potential accelerated approval pathways in colorectal cancer and Ewing sarcoma, subject to ongoing data trends. For INBRX-106, enrollment was completed in the checkpoint-inhibitor-refractory NSCLC cohort and in the Phase 2 portion of the HNSCC trial, with initial Phase 2 results expected in the second quarter of 2026 and PFS data planned for the fourth quarter of 2026.
Insider transactions
Open-market activity, trailing 12 months: 20 purchases ($6.3M), 5 sales ($279K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-14 | Lappe Mark · director, Chief Executive Officer | Open-market purchase | 2,470 | $84.07 | $208K | Form 4 |
| 2026-10-14 | Lappe Mark · director, Chief Executive Officer | Open-market purchase | 2,470 | $85.00 | $210K | Form 4 |
| 2026-10-14 | Lappe Mark · director, Chief Executive Officer | Open-market purchase | 100 | $85.76 | $9K | Form 4 |
| 2026-10-14 | Lappe Mark · director, Chief Executive Officer | Open-market purchase | 2,449 | $84.07 | $206K | Form 4 |
| 2026-10-14 | Lappe Mark · director, Chief Executive Officer | Open-market purchase | 2,451 | $85.00 | $208K | Form 4 |
| 2026-10-14 | Lappe Mark · director, Chief Executive Officer | Open-market purchase | 100 | $85.76 | $9K | Form 4 |
| 2026-09-28 | Lappe Mark · director, Chief Executive Officer | Open-market purchase | 1,500 | $98.88 | $148K | Form 4 |
| 2026-09-28 | Lappe Mark · director, Chief Executive Officer | Open-market purchase | 3,000 | $101.70 | $305K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 135 reporting institutions held 12.7M shares ($853.7M, 86.1% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | PERCEPTIVE ADVISORS LLC | 1,442,707 | $97.0M |
| 2 | VIKING GLOBAL INVESTORS LP | 1,437,705 | $96.7M |
| 3 | MORGAN STANLEY | 1,263,078 | $84.9M |
| 4 | Sanofi | 1,157,926 | $77.8M |
| 5 | HighTower Advisors, LLC | 870,200 | $58.5M |
| 6 | BlackRock, Inc. | 798,898 | $53.7M |
| 7 | STATE STREET CORP | 550,845 | $37.0M |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 486,422 | $32.7M |
| 9 | Sofinnova Investments, Inc. | 406,029 | $27.3M |
| 10 | Capital Research Global Investors | 392,847 | $26.4M |
| 11 | Woodline Partners LP | 384,433 | $25.8M |
| 12 | MILLENNIUM MANAGEMENT LLC | 327,860 | $22.0M |
| 13 | PFM Health Sciences, LP | 305,431 | $20.5M |
| 14 | Schonfeld Strategic Advisors LLC | 254,827 | $17.1M |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 231,509 | $15.6M |